ARGX Short Volume
argenx SE (ARGX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $50.47B, listed on NASDAQ, employing roughly 1,863 people, carrying a beta of -0.02 to the broader market. argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. Led by Karen Massey, public since 2017-05-18.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-10-14
- Short Volume
- 89.2K
- Total Volume
- 177.7K
- Short %
- 50.18%
- 30-Day Avg Short %
- 50.16%
Showing 30 days of FINRA short volume data for argenx SE.
Learn how short volume is reported and how to read the data →
Frequently asked ARGX short volume questions
- What is the daily ARGX short volume?
- As of Oct 14, 2026, argenx SE (ARGX) short volume is 89.2K shares against 177.7K total reported volume, or 50.18% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is ARGX short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does ARGX short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.